Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues

David Montani, Andrei Seferian, Florence Parent, Marc Humbert

Source: Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017

Journal Issue: August

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
David Montani, Andrei Seferian, Florence Parent, Marc Humbert. Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016
Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021
HCMV infection triggers the development of interstitial lung diseases in autoimmune disorders Source: International Congress 2014 – IPF and surroundings Year: 2014
Cellular interactions in the pathogenesis of interstitial lung diseases Source: Eur Respir Rev 2015; 24: 102-114 Year: 2015
Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010
Interstitial pneumonia with autoimmune features: challenges and controversies Source: Eur Respir Rev, 30 (162) 210177; 10.1183/16000617.0177-2021 Year: 2021
Late Breaking Abstract - Hypoxia-induced responses to mimic ongoing remodelling processes in chronic lung diseases Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020
Immune system dysregulation in chronic lung disease Source: Eur Respir J 2011; 38: 500-501 Year: 2011
Progress in the pathology of diffuse lung disease in infancy: changing concepts and diagnostic challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=21 Year: 2007
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019
Markers of injury and fibrosis in occupational interstitial lung diseases (OILD) Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015
Immune checkpoints in chronic obstructive pulmonary disease Source: Eur Respir Rev, 26 (144) 170045; 10.1183/16000617.0045-2017 Year: 2017
Interstitial lung diseases: a clinical update Source: Eur Respir J 2001; 18: 1S Year: 2001
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
Immune checkpoint and COPD Source: ERS Lung Science Conference 2017 Year: 2017